{"altmetric_id":17065445,"counts":{"readers":{"mendeley":26,"citeulike":1,"connotea":0},"total":{"posts_count":46},"news":{"unique_users_count":5,"unique_users":["deutsches_arzteblatt","health_canal","my_science","medicalxpress","medscape"],"posts_count":6},"blogs":{"unique_users_count":2,"unique_users":[55401,369],"posts_count":2},"twitter":{"unique_users_count":24,"unique_users":["CebdNottm","DrWalHussain1","DrSeraJames","aaron_drucker","HOMEforeczema","riddmj","USCDermatology","Links_Medicus","pediaimagen","sergiobarbaecua","Ezzoef","zecabac","intelli_pharmcy","NHSRes","DrAnjaliMahto","AMostaghimi","MarcelaSaebL","dr_rachelabbott","SkinSpecialist","jevans7","ScreamTheYellow","robertoariasr","jpmarre","med_evidence"],"posts_count":32},"facebook":{"unique_users_count":5,"unique_users":["45672742814","107118352655018","232365243452292","167897836607917","249411015267427"],"posts_count":5},"f1000":{"unique_users_count":1,"unique_users":["F1000Prime"],"posts_count":1}},"selected_quotes":["Bullous Pemphigoid: The latest evidence to guide treatment decisions #dermatology #dermpath #\u2026","Our latest publication with","Thanks for tweeting - we're trying to make sure dermatologists and people with BP alike see the study, no matter where they\u2026","Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid","Doxycycline versus prednisolone for bullous pemphigoid"],"citation":{"abstract":"Bullous pemphigoid is a blistering skin disorder with increased mortality. We tested whether a strategy of starting treatment with doxycycline gives acceptable short-term blister control while conferring long-term safety advantages over starting treatment with oral corticosteroids.\nWe did a pragmatic, multicentre, parallel-group randomised controlled trial of adults with bullous pemphigoid (three or more blisters at two or more sites and linear basement membrane IgG or C3). Participants were randomly assigned to doxycycline (200 mg per day) or prednisolone (0\u00b75 mg\/kg per day) using random permuted blocks of randomly varying size, and stratified by baseline severity (3-9, 10-30, and >30 blisters for mild, moderate, and severe disease, respectively). Localised adjuvant potent topical corticosteroids (<30 g per week) were permitted during weeks 1-3. The non-inferiority primary effectiveness outcome was the proportion of participants with three or fewer blisters at 6 weeks. We assumed that doxycycline would be 25% less effective than corticosteroids with a 37% acceptable margin of non-inferiority. The primary safety outcome was the proportion with severe, life-threatening, or fatal (grade 3-5) treatment-related adverse events by 52 weeks. Analysis (modified intention to treat [mITT] for the superiority safety analysis and mITT and per protocol for non-inferiority effectiveness analysis) used a regression model adjusting for baseline disease severity, age, and Karnofsky score, with missing data imputed. The trial is registered at ISRCTN, number ISRCTN13704604.\nBetween March 1, 2009, and Oct 31, 2013, 132 patients were randomly assigned to doxycycline and 121 to prednisolone from 54 UK and seven German dermatology centres. Mean age was 77\u00b77 years (SD 9\u00b77) and 173 (68%) of 253 patients had moderate-to-severe baseline disease. For those starting doxycycline, 83 (74%) of 112 patients had three or fewer blisters at 6 weeks compared with 92 (91%) of 101 patients on prednisolone, an adjusted difference of 18\u00b76% (90% CI 11\u00b71-26\u00b71) favouring prednisolone (upper limit of 90% CI, 26\u00b71%, within the predefined 37% margin). Related severe, life-threatening, and fatal events at 52 weeks were 18% (22 of 121) for those starting doxycycline and 36% (41 of 113) for prednisolone (mITT), an adjusted difference of 19\u00b70% (95% CI 7\u00b79-30\u00b71), p=0\u00b7001.\nStarting patients on doxycycline is non-inferior to standard treatment with oral prednisolone for short-term blister control in bullous pemphigoid and significantly safer in the long-term.\nNIHR Health Technology Assessment Programme.","altmetric_jid":"4f6fa6393cf058f610008b2a","authors":["Hywel C Williams","Fenella Wojnarowska","Gudula Kirtschig","James Mason","Thomas R Godec","Enno Schmidt","Joanne R Chalmers","Margaret Childs","Shernaz Walton","Karen Harman","Anna Chapman","Diane Whitham","Andrew J Nunn","Williams, Hywel C","Wojnarowska, Fenella","Kirtschig, Gudula","Mason, James","Godec, Thomas R","Schmidt, Enno","Chalmers, Joanne R","Childs, Margaret","Walton, Shernaz","Harman, Karen","Chapman, Anna","Whitham, Diane","Nunn, Andrew J","J Adams","V Akhras","A Anstey","C Barnard","H Bell","S Blackford","E Br\u00f6cker","A Carmichael","R R Coelho","F Craig","K Davies","R Ellis","J English","R Gl\u00e4ser","R Groves","C G\u00fcnthert","P J Hampton","N Hepburn","R H\u00fcgel","K Hussain","J Ingram","A M Layton","N J Levell","V Lewis","H Malhomme","A Omerod","G Patel","R Rallan","J Ravenscroft","H Santander","K Steinbrink","M Sticherling","C Thomas","M Vatve","N van Beek","V Venning","E Veysey","R Wachsmuth","S Wahie","B Walker","M Walsh","J Wee","M Westmoreland","G Wong","Adam Ferguson","Indre Verpetinske","Emilia Duarte-Williamson","Fiona Antony","Chris Bower","David Gawkrodger","Kathy Taghipour","M G S Dunnill","Alex Waters","Walter Bottomley","Andrew Wright","Jane Sterling","Adzura Azam","Sam Gibbs","Thomas Luger","Ingrid Salvary","Chris Lovell","Andrew Ilchyshyn","Karen Gibbon","Marinella Nik","Robert Charles-Holmes","A Lloyd Lavery","UK Dermatology Clinical Trials Network BLISTER Study Group"],"doi":"10.1016\/s0140-6736(17)30560-3","first_seen_on":"2017-03-06T23:43:57+00:00","funders":["niehs"],"issns":["1474-547X","0140-6736","01406736"],"issue":"10079","journal":"The Lancet","last_mentioned_on":1499188398,"links":["https:\/\/secure.jbs.elsevierhealth.com\/action\/getSharedSiteSession?rc=1&redirect=http%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flancet%2Farticle%2FPIIS0140-6736%2817%2930560-3%2Ffulltext&code=lancet-site","https:\/\/secure.jbs.elsevierhealth.com\/action\/getSharedSiteSession?rc=9&redirect=http%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flancet%2Farticle%2FPIIS0140-6736%2817%2930560-3%2Ffulltext&code=lancet-site","https:\/\/secure.jbs.elsevierhealth.com\/action\/getSharedSiteSession?rc=9&redirect=http%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flancet%2Farticle%2FPIIS0140-6736%2817%2930560-3%2Ffulltext%3Frss%3Dyes&code=lancet-site","https:\/\/secure.jbs.elsevierhealth.com\/action\/getSharedSiteSession?rc=1&redirect=http%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flancet%2Farticle%2FPIIS0140-6736%252817%252930560-3%2Ffulltext&code=lancet-site","http:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(17)30560-3\/fulltext?elsca1=tlxpr","http:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(17)30560-3\/fulltext","http:\/\/dx.doi.org\/10.1016\/S0140-6736(17)30560-3","http:\/\/thelancet.com\/journals\/lancet\/article\/PIIS0140-6736%2817%2930560-3\/fulltext?elsca1=tlxpr#.WL8Zug2bsaQ.twitter","http:\/\/thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(17)30560-3\/abstract","http:\/\/thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(17)30560-3\/abstract#.WL8ou8ECv9s.facebook","https:\/\/secure.jbs.elsevierhealth.com\/action\/getSharedSiteSession?redirect=http%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flancet%2Farticle%2FPIIS0140-6736%2817%2930560-3%2Ffulltext%3Felsca1%3Detoc&rc=0&code=lancet-site","https:\/\/secure.jbs.elsevierhealth.com\/action\/getSharedSiteSession?rc=2&redirect=http%3A%2F%2Fthelancet.com%2Fjournals%2Flancet%2Farticle%2FPIIS0140-6736%2817%2930560-3%2Fabstract&code=lancet-site","http:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(17)30560-3\/fulltext?rss=yes","https:\/\/secure.jbs.elsevierhealth.com\/action\/getSharedSiteSession?rc=3&redirect=http%3A%2F%2Fthelancet.com%2Fjournals%2Flancet%2Farticle%2FPIIS0140-6736%2817%2930560-3%2Ffulltext%3Felsca1%3Detoc&code=lancet-site","http:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736%2817%2930560-3\/fulltext#.WMPW2VWIhac.twitter","https:\/\/secure.jbs.elsevierhealth.com\/action\/getSharedSiteSession?redirect=http%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flancet%2Farticle%2FPIIS0140-6736%2817%2930560-3%2Ffulltext&rc=0&code=lancet-site","https:\/\/secure.jbs.elsevierhealth.com\/action\/getSharedSiteSession?rc=2&redirect=http%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flancet%2Farticle%2FPIIS0140-6736%2817%2930560-3%2Ffulltext&code=lancet-site","https:\/\/secure.jbs.elsevierhealth.com\/action\/getSharedSiteSession?redirect=http%3A%2F%2Fthelancet.com%2Fjournals%2Flancet%2Farticle%2FPIIS0140-6736%2817%2930560-3%2Fabstract&rc=0&code=lancet-site","https:\/\/secure.jbs.elsevierhealth.com\/action\/getSharedSiteSession?rc=4&redirect=http%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flancet%2Farticle%2FPIIS0140-6736%252817%252930560-3%2Ffulltext&code=lancet-site","http:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(17)30560-3\/abstract","https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28279484","http:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736%2817%2930560-3\/fulltext?elsca1=etoc#.WPrDzpWJrMg.twitter","http:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(17)30560-3\/fulltext?elsca1=etoc","http:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(17)30560-3\/fulltext?elsca1=etoc#.WP0i6E8H-ak.facebook","http:\/\/thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(17)30560-3\/fulltext","https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5400809\/"],"pdf_url":"http:\/\/thelancet.com\/article\/S0140673617305603\/pdf","pmid":"28279484","pubdate":"2017-03-06T00:00:00+00:00","publisher":"Elsevier","publisher_subjects":[{"name":"Medical And Health Sciences","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences"],"startpage":"1630","subjects":["medicine"],"title":"Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial","type":"article","volume":"389","mendeley_url":"http:\/\/www.mendeley.com\/research\/doxycycline-versus-prednisolone-initial-treatment-strategy-bullous-pemphigoid-pragmatic-noninferiori"},"altmetric_score":{"score":66,"score_history":{"1y":66,"6m":12.25,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":66},"context_for_score":{"all":{"total_number_of_other_articles":8461697,"mean":7.1088157534769,"rank":143168,"this_scored_higher_than_pct":98,"this_scored_higher_than":8318393,"rank_type":"exact","sample_size":8461697,"percentile":98},"similar_age_3m":{"total_number_of_other_articles":244787,"mean":13.72503760836,"rank":9849,"this_scored_higher_than_pct":95,"this_scored_higher_than":234926,"rank_type":"exact","sample_size":244787,"percentile":95},"this_journal":{"total_number_of_other_articles":24610,"mean":27.945876061603,"rank":1977,"this_scored_higher_than_pct":91,"this_scored_higher_than":22633,"rank_type":"exact","sample_size":24610,"percentile":91},"similar_age_this_journal_3m":{"total_number_of_other_articles":556,"mean":71.731863063063,"rank":96,"this_scored_higher_than_pct":82,"this_scored_higher_than":460,"rank_type":"exact","sample_size":556,"percentile":82}}},"demographics":{"poster_types":{"member_of_the_public":14,"researcher":1,"practitioner":8,"science_communicator":1},"users":{"twitter":{"cohorts":{"Members of the public":14,"Practitioners (doctors, other healthcare professionals)":8,"Scientists":1,"Science communicators (journalists, bloggers, editors)":1}},"mendeley":{"by_status":{"Unspecified":2,"Librarian":3,"Researcher":4,"Student  > Doctoral Student":1,"Student  > Ph. D. Student":1,"Student  > Postgraduate":3,"Other":7,"Student  > Master":1,"Student  > Bachelor":2,"Professor":2},"by_discipline":{"Medicine and Dentistry":19,"Physics and Astronomy":1,"Psychology":1,"Immunology and Microbiology":1,"Nursing and Health Professions":1,"Unspecified":2,"Environmental Science":1}}},"geo":{"twitter":{"GB":7,"CA":1,"US":3,"EC":1,"BR":1,"JP":2,"CO":1,"FR":1}}},"posts":{"news":[{"title":"Doxycyclin lindert bullses Pemphigoid (07.03.2017)","url":"http:\/\/ct.moreover.com\/?a=29818917534&p=1pl&v=1&x=wrMntPePwn1mO0ltXIJeMA","license":"public","citation_ids":[17065445],"posted_on":"2017-03-07T17:18:00+00:00","summary":"Medizin Dienstag, 7. Mrz 2017 Nottingham Eine orale Behandlung mit Doxycyclin ist beim bullsen Pemphigoid, einer lebensgefhrlichen blasenbildenden Autoimmunerkrankung der Haut, eine beliebte Alternative zur hochdosierten Prednisolon-Gabe.","author":{"name":"Deutsches \u00c4rzteblatt","url":"http:\/\/www.aerzteblatt.de\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/970\/normal\/image.png?1403704977"}},{"title":"Clinical trial reveals a safer long term treatment for blistering skin disease - Healthcanal.com","url":"http:\/\/ct.moreover.com\/?a=29813551921&p=1pl&v=1&x=4AfpwDkj_ykAxpYPxeqCMA","license":"public","citation_ids":[17065445],"posted_on":"2017-03-07T08:36:20+00:00","summary":"A clinical trial into the treatment of the severe blistering skin condition \u2018bullous pemphigoid\u2019 has found that starting treatment with an oral antibiotic is an effective and safer alternative to the current standard treatment of oral steroids which\u2026","author":{"name":"Health Canal","url":"http:\/\/www.healthcanal.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/221\/normal\/image.png?1370446573"}},{"title":"Clinical trial reveals a safer long term treatment for blistering skin disease","url":"http:\/\/ct.moreover.com\/?a=29811655865&p=1pl&v=1&x=5WrlP-1U3bEJpcVzJTxxEQ","license":"public","citation_ids":[17186597,17065445],"posted_on":"2017-03-06T21:30:00+00:00","summary":"A clinical trial into the treatment of the severe blistering skin condition \u2018bullous pemphigoid\u2019 has found that starting treatment with an oral antibiotic is an effective and safer alternative to the current standard treatment of oral steroids which\u2026","author":{"name":"My Science","url":"http:\/\/www.myscience.org\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/002\/019\/normal\/Screen_Shot_2016-02-18_at_12.34.10.png?1455798875"}},{"title":"Clinical trial reveals a safer long term treatment for blistering skin disease","url":"http:\/\/ct.moreover.com\/?a=29815632921&p=1pl&v=1&x=jTrlOaTeXdkyeIhliXm_Jw","license":"public","citation_ids":[17186597,17065445],"posted_on":"2017-03-07T13:43:42+00:00","summary":"Credit: University of Nottingham A clinical trial into the treatment of the severe blistering skin condition 'bullous pemphigoid' has found that starting treatment with an oral antibiotic is an effective and safer alternative to the current standard\u2026","author":{"name":"MedicalXpress","url":"http:\/\/medicalxpress.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/152\/normal\/image.png?1369925783"}},{"title":"Doxycycline a First-line Choice for Bullous Pemphigoid?","url":"http:\/\/ct.moreover.com\/?a=29921969442&p=1pl&v=1&x=JXqopH3jH5xU0KfU6qUdLw","license":"public","citation_ids":[17065445,17451168,17451168],"posted_on":"2017-03-16T21:35:06+00:00","summary":"Reuters Health Information By Reuters Staff | March 16, 2017 NEW YORK (Reuters Health) \u2013 For patients with bullous pemphigoid, doxycycline as initial treatment provides acceptable short-term blister control and is safer in the long-term than upfront\u2026","author":{"name":"Medscape","url":"http:\/\/medscape.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/055\/normal\/medscape.png?1369846939"}},{"title":"Bull\u00f6ses Pemphigoid: Doxycyclin als Alternative zu Steroiden?","url":"http:\/\/ct.moreover.com\/?a=30572063969&p=1pl&v=1&x=4GeO_Svyvb31RPLBbQpNvw","license":"public","citation_ids":[17065445,17451168],"posted_on":"2017-05-15T09:49:31+00:00","summary":"Patienten mit bull\u00f6sem Pemphigoid erhalten zur Therapie u.a. systemische Glucocorticoide.","author":{"name":"Medscape","url":"http:\/\/medscape.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/055\/normal\/medscape.png?1369846939"}}],"twitter":[{"url":"http:\/\/twitter.com\/CebdNottm\/statuses\/838897892488273925","license":"gnip","citation_ids":[17065445],"posted_on":"2017-03-06T23:43:38+00:00","author":{"name":"Dermatology Nottm","url":"http:\/\/www.nottingham.ac.uk\/dermatology","image":"https:\/\/pbs.twimg.com\/profile_images\/573136034399059968\/nZhrQgVu_normal.jpeg","description":"Centre of Evidence Based Dermatology,  @UniofNottingham. We conduct independent research into skin disease. Home to Cochrane Skin.","id_on_source":"CebdNottm","tweeter_id":"3070083965","geo":{"lt":52.9536,"ln":-1.15047,"country":"GB"},"followers":1532},"tweet_id":"838897892488273925"},{"url":"http:\/\/twitter.com\/DrWalHussain1\/statuses\/838898694636339205","license":"gnip","rt":["CebdNottm"],"citation_ids":[17065445],"posted_on":"2017-03-06T23:46:49+00:00","author":{"name":"Walayat Hussain","url":"http:\/\/drwhussain.com","image":"https:\/\/pbs.twimg.com\/profile_images\/710101448932065280\/sY1wMShZ_normal.jpg","description":"Consultant Dermatologist, Specialist Dermatological & Mohs Micrographic Surgeon | Dermatology Expert Witness | Massive All Blacks Rugby Fan","id_on_source":"DrWalHussain1","tweeter_id":"710091013407248384","geo":{"lt":53.79648,"ln":-1.54785,"country":"GB"},"followers":662},"tweet_id":"838898694636339205"},{"url":"http:\/\/twitter.com\/DrSeraJames\/statuses\/838899670235693056","license":"gnip","citation_ids":[17065445],"posted_on":"2017-03-06T23:50:42+00:00","author":{"name":"Sarah James","image":"https:\/\/pbs.twimg.com\/profile_images\/788054791477923841\/qvhpTv7-_normal.jpg","description":"Academic clinician interested in infectious diseases, public health and making the world a better place. Public Health ACF Norwich\/UEA, MPhil student.","id_on_source":"DrSeraJames","tweeter_id":"3032093667","geo":{"lt":52.2,"ln":0.11667,"country":"GB"},"followers":1130},"tweet_id":"838899670235693056"},{"url":"http:\/\/twitter.com\/aaron_drucker\/statuses\/838938366037143556","license":"gnip","citation_ids":[17065445],"posted_on":"2017-03-07T02:24:27+00:00","author":{"name":"Aaron Drucker","url":"https:\/\/vivo.brown.edu\/display\/adrucker","image":"https:\/\/pbs.twimg.com\/profile_images\/674315949990899713\/4GLYkUAp_normal.png","description":"Academic Dermatologist, focusing on eczema (atopic dermatitis) epidemiology.","id_on_source":"aaron_drucker","tweeter_id":"4063414312","geo":{"lt":43.70011,"ln":-79.4163,"country":"CA"},"followers":126},"tweet_id":"838938366037143556"},{"url":"http:\/\/twitter.com\/HOMEforeczema\/statuses\/839082435212099584","license":"gnip","rt":["CebdNottm"],"citation_ids":[17065445],"posted_on":"2017-03-07T11:56:56+00:00","author":{"name":"HOME for eczema","image":"https:\/\/pbs.twimg.com\/profile_images\/809349215264575488\/QIR20Bm__normal.jpg","description":"HOME is an international group working together to agree core outcome sets for eczema clinical trials and clinical record-keeping http:\/\/www.homeforeczema.org\/","id_on_source":"HOMEforeczema","tweeter_id":"809347023988260864","geo":{"lt":null,"ln":null},"followers":138},"tweet_id":"839082435212099584"},{"url":"http:\/\/twitter.com\/riddmj\/statuses\/839213257416183810","license":"gnip","citation_ids":[17065445],"posted_on":"2017-03-07T20:36:47+00:00","author":{"name":"Matthew Ridd","url":"http:\/\/www.bristol.ac.uk\/social-community-medicine\/people\/person\/matthew-j-ridd\/overview.html","image":"https:\/\/pbs.twimg.com\/profile_images\/550770502793314305\/X3vpeEzM_normal.png","description":"GP & researcher @capcbristol - skin conditions & allergy, patient-doctor relationships, self-management of healthcare","id_on_source":"riddmj","tweeter_id":"251170290","geo":{"lt":51.45523,"ln":-2.59665,"country":"GB"},"followers":1098},"tweet_id":"839213257416183810"},{"url":"http:\/\/twitter.com\/CebdNottm\/statuses\/839263025542606848","license":"gnip","rt":["riddmj"],"citation_ids":[17065445],"posted_on":"2017-03-07T23:54:32+00:00","author":{"name":"Dermatology Nottm","url":"http:\/\/www.nottingham.ac.uk\/dermatology","image":"https:\/\/pbs.twimg.com\/profile_images\/573136034399059968\/nZhrQgVu_normal.jpeg","description":"Centre of Evidence Based Dermatology,  @UniofNottingham. We conduct independent research into skin disease. Home to Cochrane Skin.","id_on_source":"CebdNottm","tweeter_id":"3070083965","geo":{"lt":52.9536,"ln":-1.15047,"country":"GB"},"followers":1532},"tweet_id":"839263025542606848"},{"url":"http:\/\/twitter.com\/USCDermatology\/statuses\/839306067418869760","license":"gnip","rt":["healourskin"],"citation_ids":[17065445],"posted_on":"2017-03-08T02:45:34+00:00","author":{"name":"USC Dermatology","url":"http:\/\/dermatology.keckmedicine.org\/","image":"https:\/\/pbs.twimg.com\/profile_images\/593866099311017984\/HWvqD6Ph_normal.jpg","description":"Official account for the Dept. of Dermatology at the Keck of School of Medicine of USC. Interested patients, please call 323-442-6200.","id_on_source":"USCDermatology","tweeter_id":"3180907718","geo":{"lt":34.05223,"ln":-118.24368,"country":"US"},"followers":566},"tweet_id":"839306067418869760"},{"url":"http:\/\/twitter.com\/Links_Medicus\/statuses\/840176010746314754","license":"gnip","rt":["CebdNottm"],"citation_ids":[17065445],"posted_on":"2017-03-10T12:22:25+00:00","author":{"name":"LinksMedicus.com","url":"https:\/\/linksmedicus.com\/","image":"https:\/\/pbs.twimg.com\/profile_images\/901091171103117314\/4a_XD-rc_normal.jpg","description":"Tweets on practice changing articles, guidelines and commentaries. RT = worth a look \u2260 endorsement. For free #MedEd links see our website.","id_on_source":"Links_Medicus","tweeter_id":"284102739","geo":{"lt":null,"ln":null},"followers":29951},"tweet_id":"840176010746314754"},{"url":"http:\/\/twitter.com\/pediaimagen\/statuses\/840176567183646720","license":"gnip","rt":["CebdNottm"],"citation_ids":[17065445],"posted_on":"2017-03-10T12:24:37+00:00","author":{"name":"VER\u00d3NICA DEL PRETE","image":"https:\/\/pbs.twimg.com\/profile_images\/890361729124888576\/bBttHMhl_normal.jpg","description":"Mom of #2\/Wife. IMGs. MD Candidate\/Pediatric Radiologist\n# Ultrasound#Vall Hebron#IberoRad  - Radioterapist oncology-RTOG Radiologist consultant from Venezuela.","id_on_source":"pediaimagen","tweeter_id":"3719673141","geo":{"lt":25.77427,"ln":-80.19366,"country":"US"},"followers":391},"tweet_id":"840176567183646720"},{"url":"http:\/\/twitter.com\/sergiobarbaecua\/statuses\/840206058694008833","license":"gnip","citation_ids":[17065445],"posted_on":"2017-03-10T14:21:49+00:00","author":{"name":"Sergio Barba","url":"http:\/\/www.aaaalergia.com","image":"https:\/\/abs.twimg.com\/sticky\/default_profile_images\/default_profile_normal.png","id_on_source":"sergiobarbaecua","tweeter_id":"188846475","geo":{"lt":-0.22985,"ln":-78.52495,"country":"EC"},"followers":61},"tweet_id":"840206058694008833"},{"url":"http:\/\/twitter.com\/DrWalHussain1\/statuses\/840232709922398208","license":"gnip","rt":["CebdNottm"],"citation_ids":[17065445],"posted_on":"2017-03-10T16:07:43+00:00","author":{"name":"Walayat Hussain","url":"http:\/\/drwhussain.com","image":"https:\/\/pbs.twimg.com\/profile_images\/710101448932065280\/sY1wMShZ_normal.jpg","description":"Consultant Dermatologist, Specialist Dermatological & Mohs Micrographic Surgeon | Dermatology Expert Witness | Massive All Blacks Rugby Fan","id_on_source":"DrWalHussain1","tweeter_id":"710091013407248384","geo":{"lt":53.79648,"ln":-1.54785,"country":"GB"},"followers":662},"tweet_id":"840232709922398208"},{"url":"http:\/\/twitter.com\/Ezzoef\/statuses\/840302517288370177","license":"gnip","rt":["CebdNottm"],"citation_ids":[17065445],"posted_on":"2017-03-10T20:45:06+00:00","author":{"name":"Esther van Zuuren","image":"https:\/\/pbs.twimg.com\/profile_images\/2673561307\/8c1e7934f0a802d9d9f3fba5f6090aa3_normal.jpeg","description":"Dermatologist, systematic reviewer Cochrane Collaboration, free spirit, music lover, fond of Dru yoga, travelling, books, the good things in life.","id_on_source":"Ezzoef","tweeter_id":"858280129","geo":{"lt":null,"ln":null},"followers":537},"tweet_id":"840302517288370177"},{"url":"http:\/\/twitter.com\/zecabac\/statuses\/840498985869692928","license":"gnip","citation_ids":[17065445],"posted_on":"2017-03-11T09:45:48+00:00","author":{"name":"Jose Carlos","url":"http:\/\/www.crbiodigital.com.br\/02\/josecarlos","image":"https:\/\/pbs.twimg.com\/profile_images\/1126842019\/Imagem_008_normal.jpg","id_on_source":"zecabac","tweeter_id":"45351424","geo":{"lt":-10,"ln":-55,"country":"BR"},"followers":94},"tweet_id":"840498985869692928"},{"url":"http:\/\/twitter.com\/intelli_pharmcy\/statuses\/840516337965322241","license":"gnip","citation_ids":[17065445],"posted_on":"2017-03-11T10:54:45+00:00","author":{"name":"\u9ed2\u7530\u771f\u751f(Naoki Kuroda)","url":"http:\/\/ameblo.jp\/intelligent-pharmacist","image":"https:\/\/pbs.twimg.com\/profile_images\/690880148078362624\/8VPDqoez_normal.png","description":"\u5b8c\u5168\u4e00\u4eba\u306e\u85ac\u5c40\u7d4c\u55b6\u8005\u517c\u7ba1\u7406\u85ac\u5264\u5e2b\u3002\u5ca1\u5c71\u5927\u5b66\u85ac\u5b66\u90e8\u975e\u5e38\u52e4\u8b1b\u5e2b\u306f\u4eca\u5e74\u5ea6\u3067\u8f9e\u3081\u307e\u3059\u3002\u5efa\u8a2d\u7684\u306a\u8b70\u8ad6\u306a\u3089\u3070\u3001\u3044\u3064\u3067\u3082\u3069\u306a\u305f\u304b\u3089\u3067\u3082\u304a\u53d7\u3051\u3057\u307e\u3059\u306e\u3067\u3001\u304a\u6c17\u8efd\u306b\u3002\u7b2c102\u56de\u85ac\u5264\u5e2b\u56fd\u5bb6\u8a66\u9a13\u30921\u65e51\u554f\u89e3\u8aac\u3059\u308b\u53d6\u308a\u7d44\u307f\u3001\u59cb\u3081\u307e\u3057\u305f\u3002","id_on_source":"intelli_pharmcy","tweeter_id":"4786735092","geo":{"lt":34.58333,"ln":133.76667,"country":"JP"},"followers":761},"tweet_id":"840516337965322241"},{"url":"http:\/\/twitter.com\/CebdNottm\/statuses\/840520921102323712","license":"gnip","citation_ids":[17065445],"posted_on":"2017-03-11T11:12:58+00:00","author":{"name":"Dermatology Nottm","url":"http:\/\/www.nottingham.ac.uk\/dermatology","image":"https:\/\/pbs.twimg.com\/profile_images\/573136034399059968\/nZhrQgVu_normal.jpeg","description":"Centre of Evidence Based Dermatology,  @UniofNottingham. We conduct independent research into skin disease. Home to Cochrane Skin.","id_on_source":"CebdNottm","tweeter_id":"3070083965","geo":{"lt":52.9536,"ln":-1.15047,"country":"GB"},"followers":1532},"tweet_id":"840520921102323712"},{"url":"http:\/\/twitter.com\/NHSRes\/statuses\/840530478541217793","license":"gnip","rt":["CebdNottm"],"citation_ids":[17065445],"posted_on":"2017-03-11T11:50:57+00:00","author":{"name":"NHS Research News","image":"https:\/\/pbs.twimg.com\/profile_images\/696671581842599936\/OYtwZ6ha_normal.png","description":"Sharing the latest tweets on NHS R&D in the UK. Bringing researchers together. Powered by @noclorresearch. Tweets are automated, please DM if any issues.","id_on_source":"NHSRes","tweeter_id":"4060161803","geo":{"lt":null,"ln":null},"followers":2865},"tweet_id":"840530478541217793"},{"url":"http:\/\/twitter.com\/DrAnjaliMahto\/statuses\/840535895795220480","license":"gnip","rt":["CebdNottm"],"citation_ids":[17065445],"posted_on":"2017-03-11T12:12:28+00:00","author":{"name":"Dr Anjali Mahto","url":"http:\/\/www.cedarsderm.co.uk","image":"https:\/\/pbs.twimg.com\/profile_images\/909890275694260225\/ecrYccL5_normal.jpg","description":"Consultant #Dermatologist, @cadoganclinic @cedarsderm #London. Blogger @HuffPostUK, Insta: anjalimahto #Acne #skin #yoga #travel #beauty","id_on_source":"DrAnjaliMahto","tweeter_id":"2198458504","geo":{"lt":51.50853,"ln":-0.12574,"country":"GB"},"followers":3560},"tweet_id":"840535895795220480"},{"url":"http:\/\/twitter.com\/AMostaghimi\/statuses\/840546248637763584","license":"gnip","rt":["CebdNottm"],"citation_ids":[17065445],"posted_on":"2017-03-11T12:53:36+00:00","author":{"name":"Arash Mostaghimi","url":"http:\/\/scholar.google.com\/citations?user=0VaCfdkAAAAJ&hl=en","image":"https:\/\/pbs.twimg.com\/profile_images\/641235067482705921\/xiJOFBaL_normal.jpg","description":"Medical dermatologist @brighamwomens & @harvardmed focused on identifying and promoting value in medical care. Clinical focus on inpatient consults & #alopecia","id_on_source":"AMostaghimi","tweeter_id":"485738085","geo":{"lt":42.35843,"ln":-71.05977,"country":"US"},"followers":378},"tweet_id":"840546248637763584"},{"url":"http:\/\/twitter.com\/MarcelaSaebL\/statuses\/840547885682900996","license":"gnip","rt":["CebdNottm"],"citation_ids":[17065445],"posted_on":"2017-03-11T13:00:07+00:00","author":{"name":"Marcela SaebLima","url":"http:\/\/www.msldermatopato.com.mx\/index.html","image":"https:\/\/pbs.twimg.com\/profile_images\/898712375116877824\/ULFyysdU_normal.jpg","description":"Dermatologist & dermatopathologist (Fellowship @Harvard) @INCMNSZ @HAL @CMABC #artesan\u00edadelapoes\u00eda","id_on_source":"MarcelaSaebL","tweeter_id":"178537092","geo":{"lt":null,"ln":null},"followers":2889},"tweet_id":"840547885682900996"},{"url":"http:\/\/twitter.com\/dr_rachelabbott\/statuses\/840601448534683649","license":"gnip","rt":["CebdNottm"],"citation_ids":[17065445],"posted_on":"2017-03-11T16:32:57+00:00","author":{"name":"Rachel Abbott","image":"https:\/\/pbs.twimg.com\/profile_images\/840597918105116672\/okWfLNiz_normal.jpg","description":"Consultant dermatologist and Mohs surgeon","id_on_source":"dr_rachelabbott","tweeter_id":"730503892446920705","geo":{"lt":51.48,"ln":-3.18,"country":"GB"},"followers":56},"tweet_id":"840601448534683649"},{"url":"http:\/\/twitter.com\/Ezzoef\/statuses\/840685451069513732","license":"gnip","rt":["CebdNottm"],"citation_ids":[17065445],"posted_on":"2017-03-11T22:06:45+00:00","author":{"name":"Esther van Zuuren","image":"https:\/\/pbs.twimg.com\/profile_images\/2673561307\/8c1e7934f0a802d9d9f3fba5f6090aa3_normal.jpeg","description":"Dermatologist, systematic reviewer Cochrane Collaboration, free spirit, music lover, fond of Dru yoga, travelling, books, the good things in life.","id_on_source":"Ezzoef","tweeter_id":"858280129","geo":{"lt":null,"ln":null},"followers":537},"tweet_id":"840685451069513732"},{"url":"http:\/\/twitter.com\/SkinSpecialist\/statuses\/840820256708931584","license":"gnip","citation_ids":[17065445],"posted_on":"2017-03-12T07:02:25+00:00","author":{"name":"Sue Ibrahim","url":"http:\/\/www.elan-medical-clinic.co.uk","image":"https:\/\/pbs.twimg.com\/profile_images\/913056065482354688\/ispKLG4x_normal.jpg","description":"Nurse Consultant in Dermatology and Aesthetic Medicine. Campaigner for safety in cosmetic medicine. I say it how it is.","id_on_source":"SkinSpecialist","tweeter_id":"18673218","geo":{"lt":51.50853,"ln":-0.12574,"country":"GB"},"followers":2107},"tweet_id":"840820256708931584"},{"url":"http:\/\/twitter.com\/SkinSpecialist\/statuses\/840820395196444672","license":"gnip","rt":["CebdNottm"],"citation_ids":[17065445],"posted_on":"2017-03-12T07:02:58+00:00","author":{"name":"Sue Ibrahim","url":"http:\/\/www.elan-medical-clinic.co.uk","image":"https:\/\/pbs.twimg.com\/profile_images\/913056065482354688\/ispKLG4x_normal.jpg","description":"Nurse Consultant in Dermatology and Aesthetic Medicine. Campaigner for safety in cosmetic medicine. I say it how it is.","id_on_source":"SkinSpecialist","tweeter_id":"18673218","geo":{"lt":51.50853,"ln":-0.12574,"country":"GB"},"followers":2107},"tweet_id":"840820395196444672"},{"url":"http:\/\/twitter.com\/jevans7\/statuses\/841564200942071808","license":"gnip","rt":["CebdNottm"],"citation_ids":[17065445],"posted_on":"2017-03-14T08:18:35+00:00","author":{"name":"jennifer evans","image":"https:\/\/pbs.twimg.com\/profile_images\/1596118323\/jevans_normal.jpg","description":"Epidemiologist interested in collaborative science, evidence synthesis and more besides. Tweeting in a personal capacity.","id_on_source":"jevans7","tweeter_id":"21766799","geo":{"lt":null,"ln":null},"followers":233},"tweet_id":"841564200942071808"},{"url":"http:\/\/twitter.com\/CebdNottm\/statuses\/844151285993672705","license":"gnip","rt":["intelli_pharmcy"],"citation_ids":[17065445],"posted_on":"2017-03-21T11:38:44+00:00","author":{"name":"Dermatology Nottm","url":"http:\/\/www.nottingham.ac.uk\/dermatology","image":"https:\/\/pbs.twimg.com\/profile_images\/573136034399059968\/nZhrQgVu_normal.jpeg","description":"Centre of Evidence Based Dermatology,  @UniofNottingham. We conduct independent research into skin disease. Home to Cochrane Skin.","id_on_source":"CebdNottm","tweeter_id":"3070083965","geo":{"lt":52.9536,"ln":-1.15047,"country":"GB"},"followers":1532},"tweet_id":"844151285993672705"},{"url":"http:\/\/twitter.com\/ScreamTheYellow\/statuses\/847366596347678720","license":"gnip","citation_ids":[17065445],"posted_on":"2017-03-30T08:35:14+00:00","author":{"name":"\u85ac\u5b66\u30cb\u30f3\u30b8\u30e3(YMY)","url":"http:\/\/screamtheyellow.hatenablog.com\/","image":"https:\/\/pbs.twimg.com\/profile_images\/875283970925092864\/HxQ1KHBC_normal.jpg","description":"\u5bae\u57ce\u770c\u3067\u85ac\u5c40\u85ac\u5264\u5e2b\u3092\u3057\u3066\u304a\u308a\u307e\u3059\u3002\n\u85ac\u5264\u5e2b\u3068\u3057\u3066EBM\u3092\u3044\u304b\u306b\u5b9f\u8df5\u3057\u3066\u3044\u304f\u304b\u6a21\u7d22\u4e2d\u3067\u3059\u3002\n\u611b\u8eca\u306f\u30de\u30c4\u30c0\u30b9\u30d4\u30fc\u30c9\u30a2\u30af\u30bb\u30e9(BL3FW)\u3002\n\u5ca9\u624b\u770c\u9678\u524d\u9ad8\u7530\u5e02\u51fa\u8eab\u3002\nYMY\uff01","id_on_source":"ScreamTheYellow","tweeter_id":"798214897","geo":{"lt":38.26889,"ln":140.87194,"country":"JP"},"followers":1539},"tweet_id":"847366596347678720"},{"url":"http:\/\/twitter.com\/CebdNottm\/statuses\/848461503846133762","license":"gnip","citation_ids":[17065445],"posted_on":"2017-04-02T09:06:00+00:00","author":{"name":"Dermatology Nottm","url":"http:\/\/www.nottingham.ac.uk\/dermatology","image":"https:\/\/pbs.twimg.com\/profile_images\/573136034399059968\/nZhrQgVu_normal.jpeg","description":"Centre of Evidence Based Dermatology,  @UniofNottingham. We conduct independent research into skin disease. Home to Cochrane Skin.","id_on_source":"CebdNottm","tweeter_id":"3070083965","geo":{"lt":52.9536,"ln":-1.15047,"country":"GB"},"followers":1532},"tweet_id":"848461503846133762"},{"url":"http:\/\/twitter.com\/robertoariasr\/statuses\/855613733938319360","license":"gnip","citation_ids":[17065445],"posted_on":"2017-04-22T02:46:25+00:00","author":{"name":"Roberto Arias","image":"https:\/\/pbs.twimg.com\/profile_images\/1164808391\/gatas_y_matas_018_normal.jpg","description":"Medico cirujano de la U de A, post-grado en Acupuntura China. Especialista en alivio del dolor cronico con terapias alternativas.","id_on_source":"robertoariasr","tweeter_id":"214516463","geo":{"lt":4,"ln":-72,"country":"CO"},"followers":291},"tweet_id":"855613733938319360"},{"url":"http:\/\/twitter.com\/jpmarre\/statuses\/855812610113101825","license":"gnip","citation_ids":[17065445],"posted_on":"2017-04-22T15:56:41+00:00","author":{"name":"md-fm.com","url":"http:\/\/www.md-fm.com","image":"https:\/\/pbs.twimg.com\/profile_images\/2279054607\/oglf0x5dx2398lwk3a8r_normal.jpeg","description":"Medical News from around the world with MD-FM.","id_on_source":"jpmarre","tweeter_id":"45123692","geo":{"lt":46,"ln":2,"country":"FR"},"followers":55},"tweet_id":"855812610113101825"},{"url":"http:\/\/twitter.com\/med_evidence\/statuses\/862550077142777856","license":"gnip","rt":["intelli_pharmcy"],"citation_ids":[17065445],"posted_on":"2017-05-11T06:08:58+00:00","author":{"name":"\u30e1\u30c3\u30c9\u3048\u3073\u3067\u3093\u3059","url":"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22895927","image":"https:\/\/pbs.twimg.com\/profile_images\/912550423013109760\/O4W9hG8h_normal.jpg","description":"\u30ab\u30f3\u30ca\u30d3\u30ce\u30a4\u30c9\u7cfb\uff1ahttps:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23960212\uff0cNMDA\u30fb\u30df\u30af\u30ed\u30b0\u30ea\u30a2\uff1ahttps:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27352782, https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28616020","id_on_source":"med_evidence","tweeter_id":"799444416742105088","geo":{"lt":null,"ln":null},"followers":220},"tweet_id":"862550077142777856"},{"url":"http:\/\/twitter.com\/med_evidence\/statuses\/862550953811075072","license":"gnip","citation_ids":[17065445,17065445],"posted_on":"2017-05-11T06:12:27+00:00","author":{"name":"\u30e1\u30c3\u30c9\u3048\u3073\u3067\u3093\u3059","url":"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22895927","image":"https:\/\/pbs.twimg.com\/profile_images\/912550423013109760\/O4W9hG8h_normal.jpg","description":"\u30ab\u30f3\u30ca\u30d3\u30ce\u30a4\u30c9\u7cfb\uff1ahttps:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23960212\uff0cNMDA\u30fb\u30df\u30af\u30ed\u30b0\u30ea\u30a2\uff1ahttps:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27352782, https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28616020","id_on_source":"med_evidence","tweeter_id":"799444416742105088","geo":{"lt":null,"ln":null},"followers":220},"tweet_id":"862550953811075072"}],"facebook":[{"title":"Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial","url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=10154556133257815&id=45672742814","license":"public","citation_ids":[17065445],"posted_on":"2017-03-07T21:42:21+00:00","summary":"From The Lancet:","author":{"name":"International Pemphigus & Pemphigoid Foundation","url":"https:\/\/www.facebook.com\/45672742814","facebook_wall_name":"International Pemphigus & Pemphigoid Foundation","image":"https:\/\/graph.facebook.com\/45672742814\/picture","id_on_source":"45672742814"}},{"title":"Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial","url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=1505247382842101&id=107118352655018","license":"public","citation_ids":[17065445],"posted_on":"2017-04-21T20:00:51+00:00","summary":"http:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(17)30560-3\/fulltext?elsca1=etoc","author":{"name":"Centre for Evidence-based Medicine","url":"https:\/\/www.facebook.com\/107118352655018","facebook_wall_name":"Centre for Evidence-based Medicine","image":"https:\/\/graph.facebook.com\/107118352655018\/picture","id_on_source":"107118352655018"}},{"title":"Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial","url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=1440162539339217&id=232365243452292","license":"public","citation_ids":[17065445],"posted_on":"2017-04-21T23:32:43+00:00","summary":"Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial  http:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(17)30560-3\/fulltext?elsca1=etoc","author":{"name":"Farmacologia_FMABC_News","url":"https:\/\/www.facebook.com\/232365243452292","facebook_wall_name":"Farmacologia_FMABC_News","image":"https:\/\/graph.facebook.com\/232365243452292\/picture","id_on_source":"232365243452292"}},{"title":"Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial","url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=1433028393428182&id=167897836607917","license":"public","citation_ids":[17065445],"posted_on":"2017-04-23T21:57:48+00:00","summary":"Doxycycline for bullous pemphigoid","author":{"name":"American Journal of Clinical Dermatology","url":"https:\/\/www.facebook.com\/167897836607917","facebook_wall_name":"American Journal of Clinical Dermatology","image":"https:\/\/graph.facebook.com\/167897836607917\/picture","id_on_source":"167897836607917"}},{"title":"Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial","url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=772525222956001&id=249411015267427","license":"public","citation_ids":[17065445],"posted_on":"2017-07-04T17:13:18+00:00","summary":"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5400809\/","author":{"name":"The Israeli Society of Oral Medicine","url":"https:\/\/www.facebook.com\/249411015267427","facebook_wall_name":"The Israeli Society of Oral Medicine","image":"https:\/\/graph.facebook.com\/249411015267427\/picture","id_on_source":"249411015267427"}}],"blogs":[{"title":"Doxycycline vs Steroids For Blistering Disease Bullous Pemphigoid","url":"https:\/\/medicalresearch.com\/author-interviews\/doxycycline-vs-steroids-for-blistering-disease-bullous-pemphigoid\/32822\/","license":"public","citation_ids":[17065445],"posted_on":"2017-03-11T01:38:00+00:00","summary":"MedicalResearch.com\nMedicalResearch.com Interview with: Hywel C. Williams DSc, FMedSci, NIHR Senior Investigator Director of the NIHR Health Technology Assessment Programme Professor of Dermato-Epidemiology and Co-Director of the Centre of Evidence-Based D","author":{"name":"Medical Research News and Interviews: MedicalResearch.com","url":"http:\/\/medicalresearch.com","description":"Medical Research New and Research Interviews"}},{"title":"Richard Lehman\u2019s journal review\u201420 March 2017","url":"http:\/\/blogs.bmj.com\/bmj\/2017\/03\/20\/richard-lehmans-journal-review-20-march-2017\/","license":"public","citation_ids":[17391004,17390766,17655781,17671092,17676275,17051364,17341886,17346738,17316293,17565810,16957439,17065445,17365825],"posted_on":"2017-03-20T11:59:00+00:00","summary":"NEJM&nbsp; 16 Mar 2017&nbsp; Vol 376\nStem cells for AMD\nFor sufferers of age-related macular degeneration who were hoping for a stem cell cure, this week&rsquo;s New England Journal brings bad news and shocking news. The bad news comes in a case report&nbs","author":{"name":"Latest BMJ blogs","url":"http:\/\/blogs.bmj.com\/bmj","description":"Just another blogs.bmj.com weblog"}}],"f1000":[{"title":"Recommended in F1000 Prime","url":"https:\/\/f1000.com\/prime\/727388646","license":"public","citation_ids":[17065445],"posted_on":"2017-06-14T00:00:00+00:00","f1000_classes":["good_for_teaching","technical_advance"],"f1000_score":"3"}]}}